Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication

Mario Scarpa(University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center), Maria R. Baer(U-M Rogel Cancer Center)

Oncotarget

August 31, 2021

10.18632/oncotarget.28042

Cited by 3

Related Papers

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

|Blood|2002|365

Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

|Clinical Cancer Research|2005|238

Outcome of older patients with acute myeloid leukemia

|Cancer|2013|197

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

|PLoS ONE|2013|74

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

|JAMA Oncology|2024|26